RealRate Inc., 2040 Martin Ave., Santa Clara, CA 95050

RealRate

July 10, 2026

To the CEO
Merck Co Inc
126 EAST LINCOLN AVENUE
P.O. BOX 2000
RAHWAY, NJ 07065
USA

Merck Co Inc TOP Rated in the US Pharmaceutical Ranking

Dear Sir or Madam,

at RealRate we have just published the 2026 US Pharmaceutical ranking. I am happy to inform you that Merck Co Inc has been TOP Rated at rank 15 out of 178.

Overall, 178 US companies were analyzed with respect to their financial strength. The complete rating is published at https://www.realrate.ai/rankings. Your individual rating report, showing your strengths compared to your competitors is attached.

TOP RATED 2026
RealRate

MERCK

RealRate is an international rating agency based in Santa Clara and Berlin. We use artificial intelligence to create fair and explainable company ratings. Customers highly appreciate the RealRate rating seal: only the strongest companies are able to offer highly attractive and innovative products with top customer services. Billion dollar companies rely on our rating and build trust with their customers.

You too can acquire the RealRate seal and advertise with it. We only reach out to the top-rated companies, like yours and only those may subscribe for our seal. Save a lot of money and effort compared to traditional rating agencies: get a RealRate seal for just $9,900. Simply sign the attached order form and send it back via email.

Please feel free to book a short video call with me: https://calendly.com/holger-bartel

Sincerely,

Dr. Holger Bartel, CEO

RealRate Seal Subscription

RealRate Inc.
2040 Martin Ave., Santa Clara, California 95050, USA
Via email to: holger.bartel@realrate.ai

We subscribe to the Pharmaceutical RealRate rating for Merck Co Inc. The subscription comprises the annual rating update. The invoice will be sent annually, provided that a TOP rating is achieved again. The subscription can be cancelled by written letter, effective for the following year.

RealRate provides the rating seal as a scalable vector graphic. It can be used without any restrictions by Merck Co Inc (Customer) for all promotional purposes, i.e. in product brochures, presentations, websites and broadcasting.

Item	**2026 US Pharmaceutical RealRate rating seal for Merck Co Inc**
Amount	**USD 9,900**
Order no.	2026-0000310158

Amounts payable by Customer are exclusive of taxes. Customer is responsible for all his taxes and will pay such amounts invoiced by RealRate.

Billing address

Company name		Full name	
Street address		Department	
City		Phone number	
State / provice		Email address	
ZIP code			
Country			

Shipping address
The electronic RealRate rating seal and the invoice will be sent to

Delivery email	

Merck Co Inc

Date, location, name

PHARMACEUTICAL 2026

Merck Co Inc
Rank 15 of 178



PHARMACEUTICAL 2026

Merck Co Inc
Rank 15 of 178

The relative strengths and weaknesses of Merck Co Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merck Co Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 92% points.The greatest weakness of Merck Co Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 13% points.

The company's Economic Capital Ratio, given in the ranking table, is 375%, being 145% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	43,516,000
Cost of Goods Sold	16,382,000
Intangible Assets	48,260,000
Liabilities, Current	28,327,000
Liabilities, Non-Current	0
Other Assets	19,774,000
Other Compr. Net Income	649,000
Other Expenses	3,844,000
Other Liabilities	0
Other Net Income	0
Other Revenues	65,011,000
Property and Equipment	25,316,000
Research and Development	15,789,000
Selling, General and Administrative Expense	10,733,000

Output Variable	Value in 1000 USD
Assets	136,866,000
Liabilities	28,327,000
Expenses	46,748,000
Revenues	65,011,000
Stockholders Equity	108,539,000
Net Income	18,263,000
Comprehensive Net Income	18,587,500
BaseVar	138,800,500
ECR before LimitedLiability	309%
Economic Capital Ratio	375%